Abstract:To explore the risk factors for in-stent restenosis (ISR) after stent implantation in patients with coronary heart disease (CHD) using logistic regression analysis. From February 2020 to February 2022, 350 patients with CHD after percutaneous coronary intervention (PCI) were divided into a stent stenosis group and a stent nonstenosis group based on coronary angiography results performed 2 years after PCI. Univariate and multivariate logistic regressions were used to analyze the factors related to ISR after coronary stent implantation in patients with CHD. This study was approved by the Ethics Committee of Shandong University of Traditional Chinese Medicine. Patient signed informed consent. Of the 350 patients with CHD, 138 (39.43%) had stent restenosis while 212 did not. Univariate analysis showed that a family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stent increased the risk of restenosis. The incidence of restenosis was higher in the stent group than that in the nonstent group (P < .05). There were no significant differences in the blood lipid level, left ventricular ejection fraction, clopidogrel/ticagrelor or beta-blocker withdrawal, location of culprit vessels, and thrombotic lesions between the 2 groups (P > .05). Multivariate logistic regression analysis showed that family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, aspirin withdrawal, use of conventional doses of statins, calcified lesions, ≥ 3 implanted stents, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stenting were risk factors for ISR within 2 years after PCI. A family history of CHD, history of type 2 diabetes, hypertension, smoking, and drinking, discontinuation of aspirin, use of conventional dose statins, calcified lesions, ≥ 3 stent implantations, stent length ≥ 30 mm, stent diameter < 3 mm, and tandem stenting are risk factors for ISR within 2 years after PCI in patients with CHD.

Association of ACE gene polymorphisms with in-stent restenosis by stent type (biomime, supraflex, xience)

Relationship Between the Polymorphism of Angiotensin Ⅰ Converting Enzyme Gene and Instent Restenosis after PTCA with Stent Planting

Gene polymorphism of rennin-angiotensin system and in-stent restenosis after percutaneous transluminal coronary angioplasty plus stenting

Association Between Periprocedural Myocardial Injury and Neointimal Characteristics in Patients with In-Stent Restenosis: an Optical Coherence Tomography Study.

Naturally Occurring Atherosclerosis Progression and In-stent Restenosis: Exploring Histomorphologic Associations Using Optical Coherence Tomography.

Gene Polymorphisms of the Renin-Angiotensin-Aldosterone System as Risk Factors for the Development of In-Stent Restenosis in Patients with Stable Coronary Artery Disease

Associations Between Polymorphisms of Endothelial Nitric Oxide Synthase, Matrix Metalloproteinase 3, Angiotensinogen, and Angiotensin II Type 1 Receptor and Risk of Restenosis after Percutaneous Coronary Intervention: A Meta-analysis

Joint effects of PPAR G-C161T (rs3856806) polymorphism and cardiovascular risk factors on restenosis risk after coronary stent implantation

Polymorphism K469E of Intercellular Adhesion Molecule-1 Gene and Restenosis after Coronary Stenting in Chinese Patients.

The Association Between Cyp2c19 Genotype and of In-Stent Restenosis among Patients with Vertebral Artery Stent Treatment

A Preliminary Study of Association Between the Polymorphism K469E of Intercellular Adhesion Molecule-1 Gene and Restenosis after Coronary Stenting

Incidence of Restenosis Following Rapamycin or Paclitaxeleluting Stent in Coronary Stent Implantation

A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention

The Impact of Polymorphisms Distribution of Clopidogrel Metabolism Related Gene CYP2C19 on Stent Restenosis after PCI of CHD Patients

A potential role for the <i>CDH13</i>/<i>CDH15</i> gene in repeat revascularization after first percutaneous coronary intervention

A potential role for the CDH13/CDH15 gene in repeat revascularization after first percutaneous coronary intervention.

Single-nucleotide polymorphism of ADRβ2 and CDKN1B genes in Egyptian patients with coronary artery in-stent restenosis

The association between stent type and developing angina pectoris following percutaneous coronary intervention

Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up

Risk factors for in-stent restenosis after coronary stent implantation in patients with coronary artery disease: A retrospective observational study

The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.